These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37290207)

  • 1. Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study.
    Celio L; Bartsch R; Aapro M
    J Geriatr Oncol; 2023 Jul; 14(6):101537. PubMed ID: 37290207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.
    Celio L; Cortinovis D; Cogoni AA; Cavanna L; Martelli O; Carnio S; Collovà E; Bertolini F; Petrelli F; Cassano A; Chiari R; Zanelli F; Pisconti S; Vittimberga I; Letizia A; Misino A; Gernone A; Bonizzoni E; Pilotto S; De Placido S; Bria E
    BMC Cancer; 2022 Aug; 22(1):915. PubMed ID: 35999527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
    Celio L; Cortinovis D; Cogoni AA; Cavanna L; Martelli O; Carnio S; Collovà E; Bertolini F; Petrelli F; Cassano A; Chiari R; Zanelli F; Pisconti S; Vittimberga I; Letizia A; Misino A; Gernone A; Bonizzoni E; Pilotto S; De Placido S; Bria E
    Oncologist; 2021 Oct; 26(10):e1854-e1861. PubMed ID: 34101934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
    Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
    Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
    Aapro M; Rugo H; Rossi G; Rizzi G; Borroni ME; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Lorusso V; Karthaus M; Schwartzberg L; Grunberg S
    Ann Oncol; 2014 Jul; 25(7):1328-1333. PubMed ID: 24603643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).
    Celio L; Cortinovis D; Cogoni AA; Cavanna L; Martelli O; Carnio S; Collovà E; Bertolini F; Petrelli F; Cassano A; Chiari R; Zanelli F; Pisconti S; Vittimberga I; Letizia A; Misino A; Gernone A; Bonizzoni E; Pilotto S; De Placido S; Bria E
    Sci Rep; 2023 Jan; 13(1):1257. PubMed ID: 36690734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of nausea and its impact on health-related quality of life in cisplatin-treated patients receiving dexamethasone-sparing prophylaxis: an analysis of the LUNG-NEPA study.
    Celio L; Aapro M
    Support Care Cancer; 2024 Mar; 32(3):204. PubMed ID: 38433125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
    Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
    Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
    Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
    Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis.
    Celio L; Bonizzoni E; Montani E; Aapro M
    Future Oncol; 2022 Sep; 18(30):3389-3397. PubMed ID: 36017782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
    van der Vorst MJDL; Toffoli EC; Beusink M; van Linde ME; van Voorthuizen T; Brouwer S; van Zweeden AA; Vrijaldenhoven S; Berends JC; Berkhof J; Verheul HMW
    Oncologist; 2021 Jan; 26(1):e173-e181. PubMed ID: 32735029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
    Rugo HS; Rossi G; Rizzi G; Aapro M
    Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
    Hesketh PJ; Rossi G; Rizzi G; Palmas M; Alyasova A; Bondarenko I; Lisyanskaya A; Gralla RJ
    Ann Oncol; 2014 Jul; 25(7):1340-1346. PubMed ID: 24608196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective Evaluation of a Dexamethasone Sparing Antiemetic Regimen: An Antiemetic Prophylaxis Study on NEPA (Netupitant Plus Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients.
    Agre S; Agre M; Pol P; Tonse M; Mohanty M; Shaikh A
    Cureus; 2023 Nov; 15(11):e49763. PubMed ID: 38161895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
    Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ
    Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
    Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K
    Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Shirley M
    Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
    Gralla RJ; Bosnjak SM; Hontsa A; Balser C; Rizzi G; Rossi G; Borroni ME; Jordan K
    Ann Oncol; 2014 Jul; 25(7):1333-1339. PubMed ID: 24631949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
    Schwartzberg L; Karthaus M; Rossi G; Rizzi G; Borroni ME; Rugo HS; Jordan K; Hansen V
    Cancer Med; 2019 May; 8(5):2064-2073. PubMed ID: 30968588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
    Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
    Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.